Rennova Health, Inc. 4

4 · Rennova Health, Inc. · Filed Sep 14, 2016

Form 4

Period: 2016-07-17

DirectorCEO and President

Transactions

Other
Common Stock
2016-08-05$0.30/sh+1,171,667$351,500→ 1,926,928 total(indirect: By LLC)
Award
Options to Purchase Common Stock
2016-07-17+250,000→ 250,000 total
Exercise: $0.30From: 2016-12-31Exp: 2026-07-17→ Common Stock (250,000 underlying)
Award
Options to Purchase Common Stock
2016-07-17+250,000→ 250,000 total
Exercise: $0.30From: 2018-12-31Exp: 2026-07-17→ Common Stock (250,000 underlying)
Other
Common Stock
2016-07-25$0.30/sh+333,334$100,000→ 755,261 total(indirect: By LLC)
Award
Options to Purchase Common Stock
2016-07-17+500,000→ 500,000 total
Exercise: $0.30Exp: 2026-07-17→ Common Stock (500,000 underlying)
Award
Common Stock
2016-07-17$0.30/sh+333,334$100,000→ 344,234 total
Award
Options to Purchase Common Stock
2016-07-17+250,000→ 250,000 total
Exercise: $0.30From: 2016-07-17Exp: 2026-07-17→ Common Stock (250,000 underlying)
Award
Options to Purchase Common Stock
2016-07-17+250,000→ 250,000 total
Exercise: $0.30From: 2017-12-31Exp: 2026-07-17→ Common Stock (250,000 underlying)
Award
Options to Purchase Common Stock
2016-07-17+500,000→ 500,000 total
Exercise: $0.30Exp: 2026-07-17→ Common Stock (500,000 underlying)

Footnotes (4)

[F1]Alcimede LLC received the shares in lieu of a $100,000 cash payment for services rendered.
[F2]Alcimede LLC received the shares in exchange for the cancellation of outstanding debt.
[F3]The options become first exercisable upon the Issuer attaining $75 million in gross revenue in any of the Issuer's three fiscal years from the date of grant through December 31, 2018.
[F4]The options become first exercisable upon the Issuer attaining a $100 million market capitalization at any time during the three year period ending July 17, 2019.

Documents

2 files